Aiforia is positioned to lead in AI-driven cancer diagnostics amid rising demand and declining pathologist numbers. We initiate coverage with a BUY rating and a € 3.50 price target.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Aiforia is positioned to lead in AI-driven cancer diagnostics amid rising demand and declining pathologist numbers. We initiate coverage with a BUY rating and a € 3.50 price target.
